ProShares Ultra NASDAQ Biotechnology
24 hedge funds and large institutions have $5.59M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 9 closing their positions.
0.36% more ownership
Funds ownership: 5.7% → 6.07% (+0.36%)
14% less funds holding
Funds holding: 28 → 24 (-4)
21% less capital invested
Capital invested by funds: $7.07M → $5.59M (-$1.49M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
34% less call options, than puts
Call options by funds: $1.57M | Put options by funds: $2.38M
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.68M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$715K |
| 3 |
Jane Street
New York
|
+$305K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$20.4K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$670K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
-$515K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$467K |
| 4 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
-$298K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$276K |
BIB Hedge Fund Activity: Q2 2022 in Review
24 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2022, worth a combined $5.59M — down 21% from $7.07M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BIB and 5 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $1.68M. The largest seller was Old Mission Capital, exiting entirely with an estimated $670K sold.
- 24 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2022, down from 28 in Q1 2022.
- Funds reported $5.59M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2022, down 21% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2022 and 9 closed out, a net change of -4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2022 was Citadel Advisors, an estimated $1.68M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2022 was Old Mission Capital, an estimated $670K sold.
Based on aggregated 13F filings for Q2 2022.